WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health
30.9.2025 16:00:00 EEST | Business Wire | Press release
WHOOP, the human performance company, today announced the launch of WHOOP Advanced Labs, a groundbreaking new feature that combines blood testing with continuous wearable data to deliver a complete picture of health. Members can upload past bloodwork results or schedule the company’s curated Advanced Labs panel, which tests an extensive set of biomarkers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930178710/en/
WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health
Since previewing the feature in May, more than 350,000 current WHOOP members have signed up for the waitlist, reflecting massive demand for deeper insights into human health. Starting today, members in the United States will begin gaining access, with a global rollout to follow. This announcement is the next step for WHOOP in its mission of adding one billion healthy years to people’s lives.
“WHOOP Advanced Labs bridges two worlds: lab diagnostics and 24/7 continuous monitoring,” said Will Ahmed, Founder and CEO of WHOOP. “For the first time, our members can see how their blood biomarkers and daily behaviors connect in real time. This is all part of our path to becoming a health operating system that helps our members live better and longer.”
Expert Perspectives
WHOOP developed this product in conjunction with the WHOOP Medical Advisory Board, made up of renowned doctors, researchers, and medical professionals, including Dr. Hazel Wallace, Dr. Robin Berzin, Dr. Eric Verdin and Dr. Dan Henderson.
“Bloodwork can sometimes leave people with more questions than answers,” said Dr. Hazel Wallace (MBBCh, BSc, MSc), nutritionist, author, and founder of The Food Medic. “WHOOP Advanced Labs helps bridge that gap by putting health insights directly into the hands of the individual, where habits can make a powerful difference.”
Speaking about the launch, endurance athlete, author, and podcaster Rich Roll said: “As someone who regularly gets bloodwork done, WHOOP Advanced Labs is revolutionary in helping people connect the reality of their health with themselves, and with their healthcare practitioners. To be able to see what’s on the horizon, well in advance of a problem becoming too advanced that it’s too late to deal with; I think that is fantastic.”
Proactive Health Made Personal with AI
WHOOPAdvanced Labs creates a continuous feedback loop where periodic blood tests inform daily coaching in real time. Core benefits of WHOOP Advanced Labs include:
- Testing of the most-impactful biomarkers that affect your health
- Clinician-reviewed results provide expert context and personalized recommendations
- AI-powered coaching provides daily guidance and insights
- Progress tracking shows how lifestyle adjustments influence biomarkers over time
How WHOOP Advanced Labs Works
WHOOP Advanced Labs gives members two powerful ways to bring these biomarkers into the WHOOP experience:
- Upload Any Pre-Existing Bloodwork
Members can now upload results from any lab provider directly into the WHOOP app at no additional cost. This makes it easy to centralize all results, track long-term trends, and connect them with continuous WHOOP data on sleep, training, recovery, and lifestyle. - Book Comprehensive Testing through the WHOOP app
For an even deeper experience, members can subscribe to WHOOP Advanced Labs and schedule curated blood tests directly through the WHOOP app, powered by Quest Diagnostics (NYSE: DGX) across the United States. Results are automatically synced to the WHOOP app and reviewed by a clinician who provides expert context. Subscription options include: one test for $199, two tests per year for $349, or four tests per year for $599, with additional tests available at discounted rates. Tests are reviewed and ordered by a licensed healthcare provider.
In both cases, WHOOP does what no traditional blood test can: connecting biomarker results with 24/7 physiological data to reveal how your habits and behaviors directly impact your health.
Helping Unlock One Billion Healthy Years
Earlier this year, WHOOP announced its long-term goal to add One Billion Healthy Years to people’s lives as part of its mission to unlock human performance and healthspan. Healthspan refers to the number of years someone lives in good health, free from chronic disease, functional decline, and preventable limitations. Each week, WHOOP calculates the net change in its members’ lives using the app's Healthspan feature, helping members understand how daily behaviors are adding or subtracting from their long-term healthspan. WHOOP Advanced Labs will further accelerate this work by creating a powerful feedback loop between clinical biomarkers and continuous wearable data; by testing and tracking biomarkers, providing clinician-reviewed results, and delivering performance insights. This integration of blood testing, daily monitoring, and coaching drives actionable outcomes, ultimately helping members extend both their healthspan and quality of life, and bringing WHOOP closer to its mission of unlocking One Billion Healthy Years.
PRESS KIT
Launch assets, including images and product shots, are available here.
About WHOOP
WHOOP, the human performance company, empowers people to unlock their potential and live longer, healthier lives. The WHOOP membership delivers world-class wearable technology, personalized coaching, and actionable insights across recovery, sleep, training, and health. WHOOP wearable devices, including WHOOP 5.0 and WHOOP MG, feature groundbreaking innovations such as cardiovascular health screening (including an FDA-cleared ECG), Healthspan to measure Pace of Aging and WHOOP Age, and the first-of-its-kind wearable Blood Pressure Insights.
Founded in 2012 and headquartered in Boston, WHOOP has raised more than $400 million in venture capital and ships to 56 markets worldwide. The WHOOP app is available in English, French, German, Italian, and Spanish. WHOOP is sold through leading retailers including Amazon in the U.S., U.K., and Australia, and the GCC; Best Buy and Dick’s Sporting Goods in the U.S., Flipkart in India, and Virgin Megastore and Noon in the GCC.
To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930178710/en/
Contacts
Taylor Georgeson
Jack Taylor PR
whoop@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom